Jardines completes acquisition of I-MED Radiology
Jardine Matheson Hldgs Ltd
01 October 2026
1 October 2026
Jardine Matheson Holdings Limited
Jardines completes acquisition of I-MED Radiology Network
1 October 2026 - Jardine Matheson Holdings (Jardines) today announced the completion of the acquisition of I-MED Radiology Network (I-MED), a global leader in diagnostic imaging and teleradiology based in Australia.
The investment in I-MED is a significant step for Jardines as its first major investment since its transition to an investment company in 2025. It marks the beginning of building a new earnings growth pillar for Jardines and is aligned with Jardines' strategy as an Asia Pacific-focused control owner of high-quality, scalable businesses and the 2030 objectives outlined at Jardines' Investor Day in June. As part of the transaction, Jardines will closely partner with I-MED's management team to support the company's continued growth and expansion.
Lincoln Pan, CEO of Jardine Matheson, said: "Jardines is proud to announce the completion of the acquisition of I-MED and to partner with the outstanding doctors and clinicians that make I-MED the leading radiology practice in Australia. I-MED is a trusted leader in radiology, with a long history of clinical excellence and a deep network of partners in its medical communities."
About I-MED Radiology Network
I-MED Radiology Network is the largest combined diagnostic imaging network in Australia and New Zealand, offering medical imaging and radiology services including X-ray, PET, CT, MRI, nuclear medicine, ultrasound, mammography and interventional procedures. I-MED's vision is to be the provider of choice - delivering high-quality care, accurate answers and excellent service to patients and referrers, every time - as well as to be the most respected and trusted medical imaging specialist in the world.
Across Australia and New Zealand, I-MED operates 215 clinics and performs approximately 7 million patient procedures each year, making it one of the largest providers of medical imaging globally. More than 500 radiologists and 4,000 staff share clinical knowledge and expertise across the network, ensuring a consistently high standard of service. I-MED's teleradiology operations support over 2 million patients annually, delivering 24/7 radiology reporting across Australia and New Zealand via I-TeleRAD.
Please refer to Jardine Matheson's previous announcement on the acquisition of I-MED here: https://www.jardines.com/newsroom/latest-news/strategy-and-our-portfolio/2026/announcement
Ends
About Jardines
Jardines is a diversified, Asia Pacific-focused investment company. Founded in 1832, Jardines creates value for our stakeholders by building lasting, scalable businesses in Asia Pacific that produce sustainable returns and market-leading services and products. Jardines has a primary listing on the London Stock Exchange and secondary listing in Singapore.
Find out more at www.jardines.com or visit www.i-med.com.au.
For further information, please contact:
Jardine Matheson
Graham Baker / Suzanne Cheuk +852 2843 8218 / 8262
Harry Thompson +852 2843 5343
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.